SUMMARY HIV-1 DNA exists in nonintegrated linear and circular episomal forms and as
integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear …

Abstract Human Immunodeficiency Virus (HIV) is the causative agent of Acquired
Immunodeficiency Syndrome (AIDS) with high morbidity and mortality rates. Treatment of …

Objectives The aim of this study was to assess the efficacy of dolutegravir plus lamivudine
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …

Background Dolutegravir (DTG) plus lamivudine (3TC) has proven highly efficacious as a
switching strategy in virologically suppressed people with HIV (PWH). As this strategy was …

Background: Clinical trials and real-life studies have granted the efficacy and safety of
dolutegravir and lamivudine (DTG/3TC) in naïve and experienced people living with HIV …

Introduction Second-generation integrase strand transfer inhibitors such as bictegravir (BIC)
and dolutegravir (DTG) are the standard of care for starting therapy in people living with HIV …

Background This real-world study compared the safety and effectiveness of Dolutegravir/
lamivudine (D/L) and Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy …

Objectives We evaluated virological response and resistance profiles in individuals who
were virologically suppressed who switched to bictegravir/emtricitabine/tenofovir …

Objectives We aimed to investigate and compare the efficacy and safety of two dolutegravir-
based two-drug regimens: dolutegravir+ lamivudine versus dolutegravir+ rilpivirine. Methods …

Results The H-model demonstrates superior discriminative ability, with a higher ROC-AUC
score (76.34%) than the NH-model (74.98%). Wilcoxon test results confirm significant …